TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33113161
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (1 mL)
Study: 33231281
Drug: Ketorolac group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac group (50 mg bupivacaine + 30 mg ketorolac)
Study: 33231281
Drug: Bupivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group (50 mg bupivacaine)
Study: 33827012
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy only
Study: 33891230
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: 35470300
Drug: Aggressive Hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive Hydration (vHR) with lactated Ringer's solution (3 mL/kg/h during procedure, 20 ml/kg bolus immediately afterward, then 3 mL/kg/h for another 8 hours)
Study: 35470300
Drug: High-dose Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Rectal Indomethacin (100 mg suppository immediately post-ERCP)
Study: 34258265
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+HIPEC)
Study: 33768245
Drug: Levcromakalim (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levcromakalim (0.05 mg/min infusion)
Study: 33215889
Drug: Low Amplitude
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Amplitude Seizure Therapy (LAP-ST)
Study: 33215889
Drug: Standard Right
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT)
Study: 34850952
Drug: DMARD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD treatment (increased from 17% in 1993-1997 to 52% in 2015-2019)
Study: 34850952
Drug: DMARD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD treatment
Study: 36062815
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy
Study: 33498834
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging and mailed nicotine replacement medication
Study: 33352008
Drug: PF-06823859 (SAD)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06823859 (SAD) 30, 100, 300, 900, or 2000 mg
Study: 38779539
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT)
Study: 34427687
Drug: Positive psychology
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive psychology intervention for diabetes distress; details on dosage and duration not available.
Study: 34427687
Drug: Remote protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote protocol adaptation due to COVID-19; details on dosage and duration not available.
Study: 36300304
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery
Study: 36300304
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery (in patients with PD-L1 expression level of 1% or more)
Study: 32926286
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg N and 0 mg Ni)
Study: 34214683
Drug: AC niosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC niosome gel
Study: 34214683
Drug: AC gel
Normalized name: Zantac GELdose
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC gel
Study: 34214683
Drug: Triamcinolone gel
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone gel
Study: 33991432
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) - 5 sessions including diaphragmatic breathing exercises
Study: 35332654
Drug: Liraglutide (≤1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (≤1.8 mg/day)
Study: 33399377
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral mid-axillary TAP block with 20 ml of bupivacaine 0.25% (Group T)
Study: 32506695
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with golimumab
Study: 34483247
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (8 mg/24 h) administered via Microwick device
Study: 34483247
Drug: Control (contralateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contralateral ear without treatment)
Study: 33704806
Drug: Selgantolimod (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod (1.5 mg for 2 weeks or 3 mg for 2 or 4 weeks)
Study: 38834540
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg)
Study: 36058913
Drug: Change Club
Normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change Club (CC) intervention
Study: 34922258
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (HFNC) at 20 L/min
Study: 32602616
Drug: Budesonide (tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (tapering doses from 9 to 3 mg for 12 weeks)
Study: 32307004
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg/kg every 6 hours for a total of four doses, started 6 to 12 hours prior to extubation
Study: 34625209
Drug: Once‐weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐weekly oral practice session
Study: 34882500
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg once daily bupropion
Study: 32475050
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with achieved systolic blood pressure (SBP) measurements
Study: 34046159
Drug: Ketamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine administration
Study: 35496380
Drug: Standard titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titration for the first 6 days
Study: 35526164
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg/kg)
Study: 33092327
Drug: Pilates exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates exercises (16 sessions, 60 minutes each, twice a week for 8 weeks)
Study: 32335356
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus curcumin (CUC-1®, 300 mg solution, once per week)
Study: 35285922
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (systolic BP target < 120 mm Hg)
Study: 35242206
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy alone
Study: 36122531
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (≤12 mg/day)
Study: 34663363
Drug: Betaine (BG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (BG, 2 g/day; n=14)
Study: 37811711
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics
Study: 32911733
Drug: Foot exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot exercises daily for six weeks (Group 1)
Study: 34197181
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 once every 3 weeks for three cycles before RT and 20 mg/m2 once weekly during RT)
Study: 32782729
Drug: Methadone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (5 mg/ml)
Study: 32782729
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of Opium (TOP) (10 mg/ml)
Study: 33954888
Drug: Home hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home hospital care (including nurse and physician home visits, intravenous medications, remote monitoring, video communication, and point‐of‐care testing)
Study: 34254256
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous iron (400 mg/week)
Study: 34254256
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous iron (100 mg/week)
Study: 35087753
Drug: Volumetric Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric Modulated Arc Therapy (VMAT)
Study: 35274356
Drug: Hybrid closed‐loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed‐loop insulin delivery
Study: 35274356
Drug: Sensor‐augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor‐augmented pump therapy
Study: 32520991
Drug: l-serine (594
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-serine (594 mg daily) and EPA (149 mg daily)
Study: 32520991
Drug: l-serine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-serine and EPA
Study: 33392636
Drug: Early apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Early apixaban therapy
Study: 33276145
Drug: Self-control treatment
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control treatment group (7-week smartphone-based self-control intervention)
Study: 33483173
Drug: LTH +
Normalized name: Leader Eye Health + Lutein Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTH + G advertisements
Study: 39706874
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus lifestyle intervention
Study: 37815865
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid injection
Study: 35028764
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy with light-emitting diodes (LED) applied on two acupoints (CV4 and CV6)
Study: 35028764
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with oral Marvelon, 30 µg of ethinyl estradiol and 150 µg of desogestrel (DSG/EE)
Study: 33355814
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection at anterior and posterior regions (group 2)
Study: 35786077
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in the rehab unit
Study: 32282739
Drug: Research group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research group: first bolus of 20% diluted contrast agent (1 ml/kg, upper limit 25 ml) followed by undiluted contrast agent (1 ml/kg, upper limit 25 ml).
Study: 35095912
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 500 mg/kg of Gallic Acid + transportation (TS+GA)
Study: 33990435
Drug: Catheter-directed cervical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed cervical interlaminar epidural steroid injection with triamcinolone
Study: 33990435
Drug: Cervical transforaminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical transforaminal steroid injection with dexamethasone
Study: 37591648
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy
Study: 39372262
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo
Study: 34607784
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using Ga Al As laser with a wavelength of 810nm and a power of 100 mW, applied on days 0, 3, 30, and 60 for 18 seconds each time.
Study: 34607784
Drug: Intra-oral LED
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral LED device with a wavelength of 640nm and a power density of 40 mW/cm2, used 5 minutes per day.
Study: 34607784
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment using a coated light cure device, following the same protocol as the laser group.
Study: 33844996
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 µg per actuation, 2 inhalations twice a day until symptom resolution)
Study: 35286860
Drug: Inhaled 7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 7% hypertonic saline
Study: 33734828
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atomoxetine + 2 mg biperiden hydrochloride (ato-bip)
Study: 32239737
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injection
Study: 34241801
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (FS Tablets, 0.9 g/d)
Study: 32716700
Drug: FDA-approved vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved vaccines with postapproval safety-related label modifications
Study: 32716700
Drug: FDA-approved vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved vaccines without postapproval safety-related label modifications
Study: 34705137
Drug: Early Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Botulinum toxin injection (50 U) administered 1 week before surgery
Study: 34328630
Drug: 90 mcg
Normalized name: Linzess 290 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mcg ropeginterferon alfa-2b
Study: 34328630
Drug: 180 mcg
Normalized name: Igalmi 180 MCG Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg ropeginterferon alfa-2b
Study: 34328630
Drug: 270 mcg
Normalized name: Ascorbic Acid/Biotin/Cyanocobalamin/Folic Acid/Iron/Lactobacillus casei/Niacin/Pantothenic Acid/Pyridoxine/Riboflavin/Thiamine 75 MG-270 MCG-12 MCG-1250 MCG-130 MG-6 BILLION CFU-10 MG-10 MG-10 MG-3 MG-2 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mcg ropeginterferon alfa-2b
Study: 34328630
Drug: ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ropeginterferon alfa-2b (all doses)
Study: 33033021
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral feeding formula (1.5 kcal/mL, 54% carbohydrate)
Study: 33033021
Drug: Lower carbohydrate
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower carbohydrate isocaloric enteral feeding formula (1.5 kcal/mL, 28% carbohydrate)
Study: 35810754
Drug: Bendamustine-rituximab (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine-rituximab (group B) with bendamustine at 90 mg/m2 on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1 of cycles 2–6, administered intravenously.
Study: 33957649
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied to the cervix weekly for 12 weeks
Study: 33957649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment prior to LEEP)
Study: 39001910
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC)
Study: 33878154
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) followed by Golimumab (GLM) 50 mg every 4 weeks during the OLE
Study: 35820904
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser needle acupuncture treatment
Study: 34282645
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) integrated with activity pacing for 6 sessions by a trained oncology nurse
Study: 32818112
Drug: Oral BI
Normalized name: Osteo Bi-Flex Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BI 1026706 100 mg twice daily for 12 weeks
Study: 38041077
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy
Study: 34753304
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) in BASICS trial centers
Study: 32415231
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy protocol based on Pivotal Response Treatment (PRT)
Study: 35452104
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody postexposure prophylaxis (PEP) with casirivimab and imdevimab
Study: 32593257
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + audiovisual correction
Study: 32593257
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + audiovisual correction + testosterone undecanoate
Study: 32593257
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy and escitalopram / tofisopam
Study: 34358777
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2, oral prednisone 5 mg twice daily, and oral enzalutamide 160 mg/d (arm DE)
Study: 34358777
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 and oral prednisone 5 mg twice daily (arm D)
Study: 34033270
Drug: Prazosin, uptitrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin, uptitrated to 16 mg/d
Study: 35174663
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg
Study: 33214044
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) to prostate and pelvis, dose delivered was 35–37.5 Gy to prostate and gross node, 25 Gy in five fractions to elective pelvic nodal region.
Study: 32555938
Drug: Microtexturized silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtexturized silicone implants (Lifesil®)
Study: 33360345
Drug: SMDS combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMDS combined with aspirin
Study: 32163097
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m2) followed by maintenance Pemetrexed (500 mg/m2) every 3 weeks
Study: 32163097
Drug: Docetaxel monotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel monotherapy (60 mg/m2) every 3 weeks
Study: 35514254
Drug: Reference linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference linagliptin formulation (5 mg) under fed conditions
Study: 34348455
Drug: Clofarabine 5x40
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine 5x40 mg/m2 + PEG-ASP 2,500 IU/m2
Study: 34348455
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HIDAC) 4x3g/m2 + PEG-ASP 2,500 IU/m2
Study: 34348455
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine + PEG-ASP
Study: 33653909
Drug: High-Flow Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Oxygen Therapy (HFT)
Study: 32979314
Drug: WONDFO SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China)
Study: 36897521
Drug: Individual formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual formulations (Ezetimibe and Rosuvastatin)
Study: 36897521
Drug: Ezetimibe/Rosuvastatin fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Rosuvastatin fixed dose combination (10 mg/10 mg)
Study: 32301407
Drug: Cranberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry beverage (450 ml daily for 8 weeks)
Study: 32365398
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg/day)
Study: 35796392
Drug: Prednisone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.5 mg/kg/day orally for 7 days, followed by a decreasing dosage for another week
Study: 35796392
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid therapy
Study: 32653606
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of mifepristone every other day for two months followed by insertion of an LNG-IUS 52 mg
Study: 36387992
Drug: 3 60‐min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 60‐min sessions of Brief Prolonged Exposure Therapy (Brief PE)
Study: 33154284
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine 10 mg every 30 min up to 5 doses
Study: 33154284
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine 20 mg every 30 min up to 5 doses
Study: 33154284
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine and intravenous hydralazine
Study: 35450742
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg per day
Study: 34544853
Drug: Task-specific motor
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-specific motor therapy (20 extra hours) starting at ≤30 days after stroke (acute)